Dow Up0.66% Nasdaq Up0.88%

Anthera Pharmaceuticals, Inc. (ANTH)

3.57 Down 0.13(3.51%) May 2, 4:00PM EDT
ProfileGet Profile for:
Anthera Pharmaceuticals, Inc.
25801 Industrial Boulevard
Suite B
Hayward, CA 94545
United States - Map
Phone: 510-856-5600
Fax: 510-856-5597

Index Membership:N/A
Full Time Employees:20

Business Summary 

Anthera Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for patients with unmet medical needs. The company’s Phase III product candidates include liprotamase or Sollpura, a non-porcine investigational pancreatic enzyme replacement therapy for the treatment of patients with exocrine pancreatic insufficiency; and Blisibimod that targets B-cell activating factor associated with various B-cell mediated autoimmune diseases, including systemic lupus erythematosus, lupus nephritis, and others. It also develops Blisibimod, which is in Phase II clinical study for the treatment of Immunoglobulin A nephropathy. The company was founded in 2004 and is headquartered in Hayward, California.

Key Statistics

Company Websites 
Home Page
Search Yahoo! for:
More on Anthera Pharmaceuticals, Inc.

Corporate Governance 
Anthera Pharmaceuticals, Inc.’s ISS Governance QuickScore as of May 1, 2016 is 9. The pillar scores are Audit: 2; Board: 6; Shareholder Rights: 8; Compensation: 9.
Brought to you by Institutional Shareholder Services (ISS)

Key Executives 
Mr. Paul F. Truex MBA, 47
Chief Exec. Officer and Director
Ms. May Liu , 40
Chief Accounting Officer & Compliance Officer and Sr. VP of Fin. & Admin.
Ms. Klara A. Dickinson-Eason , 48
Chief Regulatory Officer and Sr. VP
Dr. Debra Odink Ph.D., 52
Mr. John Craig Thompson , 49
Pres and Chief Operating Officer
Amounts are as of Dec 31, 2015 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
Currency in USD.
View Insiders